Search
Last week, Governor Kathy Hochul signed the New York State Budget for FY 2023 that includes a key provision which will allow more New Yorkers from underserved communities access to care at Memorial Sloan Kettering Cancer Center (MSK) and other NCI-designated cancer centers in the state.
La semana pasada, la gobernadora Kathy Hochul firmó el presupuesto del estado de Nueva York para el año fiscal 2023, que incluye una disposición clave que permitirá que más neoyorquinos de comunidades marginadas accedan a la atención en Memorial Sloan Kettering Cancer Center (MSK) y otros centros oncológicos designados por el Instituto Nacional del Cáncer (NCI) en el estado.
In this interview, hematologic oncologist Eytan Stein, Director of the Program for Drug Development in Leukemia, talks about the latest advances in treatment for AML and how people can benefit from receiving their treatment at MSK.
Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). This year’s commencement marks the school’s 11th graduating class since admitting its first students in 2006.
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:
Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.
Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer.
The MSK team’s goal was to get at the underlying defects in cells that these mutations cause.
Laboratory studies have revealed an explanation for why androgen-deprivation therapy makes radiation therapy more effective in the treatment of high-risk prostate cancer.